After a string of lackluster deals, the biotech industry is looking to four debutants expected to price first-time share sales in the coming weeks to see if they can reignite the sector.
Drug developers that have raised more than $10 million in US initial public offerings this year have largely faltered with six of the 11 firms diving below their debut prices and the median decliner trading 45% below the offer price, data compiled by Bloomberg show.
The likes of
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.